Literature DB >> 17131243

In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in Plasmodium vivax.

Leila Kyavar1, Chaiporn Rojanawatsirivet, Herwig Kollaritsch, Gunther Wernsdorfer, Jeeraphat Sirichaisinthop, Walther H Wernsdorfer.   

Abstract

Malaria resulting from infection with Plasmodium vivax rarely causes death, however, patients usually suffer acute debilitating clinical symptoms and the recovery is slow. This study had the objective of assessing the pharmacodynamic interaction between artimisinin and chloroquine with a view of a potential acceleration of the clinicalparasitological response, and the investigation of therapeutic alternatives in the event of chloroquine resistance in Plasmodium vivax. Tests were based on the growth inhibition of Plasmodium vivax, determined by morphological differential counts of 200 asexual parasites. In total 45 isolates were evaluated successfully with parallel tests for artemisinin, chloroquine and desbutylbenflumetol (DBB) alone and combinations of artemisinin + chloroquine and artemisinin + DBB. Total inhibition was reached at a mean concentration of 1274.8 nM (95% CI 898.5 to 1808.7 nM), and 1852.2 nM (95% CI 1539.5 to 2228.6 nM) for artemisinin, and chloroquine respectively, whilst the 1:1 (m/m) combination of artemisinin and chloroquine was 1860.2 nM (95% CI 1454.4 to 2379.3 nM). EC(50) and EC(90) were 129.9 nM and 1058.5 nM for chloroquine, 32.6 nM and 735.5 nM for artemisinin, and 73.6 nM and 1103.0 nM for the 1:1 combination of both drugs. Interaction analysis according to Berenbaum yielded for the artemisinin + chloroquine combination at the EC(50) a mean SigmaFIC of 1.1126, at the EC(90) a mean SigmaFIC of 1.0331, and at the EC(99) a mean SigmaFIC of 1.1857. These results revealed marked additive interaction. For desbutylbenflumetol (DBB) the EC(50) and EC(90) were 1.5 nM and 28.8 nM, complete growth inhibition was observed at 90.4 nM (95% CI 75.1 to 108.7 nM). Interaction analysis indicated moderate antagonism at the lower concentration ranges, at the EC(90) additive interaction with a mean SigmaFIC of 1.0300, and synergism at the therapeutically most important EC(99) with a mean SigmaFIC of 0.5990.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17131243     DOI: 10.1007/s00508-006-0677-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  11 in total

1.  Plasmodium vivax resistance to chloroquine?

Authors:  K H Rieckmann; D R Davis; D C Hutton
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

2.  Desbutyl-benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand.

Authors:  H Noedl; T Allmendinger; S Prajakwong; G Wernsdorfer; W H Wernsdorfer
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

4.  Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand.

Authors:  Daniela K Pirker-Krassnig; Gunther Wernsdorfer; Jeeraphat Sirichaisinthop; Chaiporn Rojanawatsirivet; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2004       Impact factor: 1.704

Review 5.  Malaria at the turn from the 2nd to the 3rd millenium.

Authors:  Gunther Wernsdorfer; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2003       Impact factor: 1.704

Review 6.  Coartemether (artemether and lumefantrine): an oral antimalarial drug.

Authors:  Walther H Wernsdorfer
Journal:  Expert Rev Anti Infect Ther       Date:  2004-04       Impact factor: 5.091

7.  Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.

Authors:  Martin Traebert; Bérengère Dumotier; Lothar Meister; Peter Hoffmann; Manuel Dominguez-Estevez; Willi Suter
Journal:  Eur J Pharmacol       Date:  2004-01-19       Impact factor: 4.432

8.  Clinical-parasitological response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand.

Authors:  Oumaporn Tasanor; Ronnatrai Ruengweerayut; Jeerapat Sirichaisinthop; Kanungnit Congpuong; Walther H Wernsdorfer; Kesara Na-Bangchang
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-02-23       Impact factor: 2.184

9.  Sensitivity of Plasmodium vivax to chloroquine in Sa Kaeo Province, Thailand.

Authors:  K Congpuong; K Na-Bangchang; K Thimasarn; U Tasanor; W H Wernsdorfer
Journal:  Acta Trop       Date:  2002-08       Impact factor: 3.112

10.  An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine.

Authors:  Oumaporn Tasanor; Harald Noedl; Kesara Na-Bangchang; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Acta Trop       Date:  2002-07       Impact factor: 3.112

View more
  3 in total

1.  Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome.

Authors:  Rina P M Wong; Sam Salman; Kenneth F Ilett; Peter M Siba; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

2.  Synergism between monodesbutyl-benflumetol and artemisinin in Plasmodium falciparum in vitro.

Authors:  Gernot Müller; Gunther Wernsdorfer; Jeeraphat Sirichaisinthop; Peter Starzengruber; Kanungnit Congpuong; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

3.  Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.

Authors:  Manase Kilonzi; Omary Minzi; Ritah Mutagonda; Vito Baraka; Philip Sasi; Eleni Aklillu; Appolinary Kamuhabwa
Journal:  Malar J       Date:  2020-02-11       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.